Respiratory syncytial virus (RSV) is the single most important viral pathogen causing acute lower respiratory- tract infections (bronchiolitis) in children. No vaccine or specific therapy is currently licensed to prevent and treat RSV infections. Exposure to environmental tobacco smoke (ETS) has been identified as a risk factor for the development of severe RSV infections, yet the mechanisms that determine ETS and infection co-morbidity are largely unknown. Recent studies support the notion that severity of clinical disease is driven by higher level of RSV replication in the airways and studies by our group have shown that expression and activity of superoxide dismutase (SOD) antioxidant enzymes are significantly decreased in the airways of infants with severe episodes of RSV bronchiolitis, particularly if infants had been exposed to ETS. Surprisingly, our new preliminary data have shown that SOD enzymes are able to inhibit RSV replication in cultured epithelial cells and in experimentally-infected mice. We propose the novel hypothesis that lung SOD enzymes have a previously unrecognized function as host antiviral gene products by limiting RSV replication and shortening viral shedding. Our secondary hypothesis is that expression and antiviral function of such enzymes are reduced/impaired in RSV-infected subjects who are exposed to ETS. In this exploratory project we propose to test these hypotheses by two Specific Aims.
In Aim 1, the profile, relative abundance, and activity of SOD proteins will be analyzed in nasopharyngeal secretions (NPS) of infants with RSV infections of different clinical severity and with or without exposure to ETS. SOD levels and activity will be correlated with the concentration (i.e. viral titer/load) of RSV in NPS.
In Aim 2, we will test the specific hypothesis that increasing of SOD activity in the lungs will blunt RSV replication and improve airway disease. For that, we will increase SOD expression in the lung by adeno-associated virus (AAV)-mediated gene transfer or by the use of salen-based EUK SOD mimetics, and measure RSV titer (as the main endpoint) in an experimental mouse model of RSV infection and co-exposure to ETS. The protective effect of SOD will be evaluated by examining clinical disease, lung inflammation/pathology, and viral-mediated airway hyperresponsiveness. This project may have important translational implications by suggesting new and more aggressive strategies to treat primary respiratory viral infections in high risk infants (i.e. those exposed to ETS). These therapeutic opportunities will b explored in a future R01 application based on the results of this exploratory project.

Public Health Relevance

The results of this project will provide a better understanding of the molecular mechanisms by which exposure to environmental tobacco smoke affects the severity of viral bronchiolitis in infants. These findings should have important therapeutic implications by identifying new strategies to treat viral bronchiolitis or exacerbations of chronic lung diseases that are associated with exposure to tobacco smoke.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Exploratory/Developmental Grants (R21)
Project #
Application #
Study Section
Innate Immunity and Inflammation Study Section (III)
Program Officer
Kim, Sonnie
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas Medical Br Galveston
Schools of Medicine
United States
Zip Code
Ivanciuc, Teodora; Sbrana, Elena; Ansar, Maria et al. (2016) Hydrogen Sulfide Is an Antiviral and Antiinflammatory Endogenous Gasotransmitter in the Airways. Role in Respiratory Syncytial Virus Infection. Am J Respir Cell Mol Biol 55:684-696
Garofalo, Roberto P; Kolli, Deepthi; Casola, Antonella (2013) Respiratory syncytial virus infection: mechanisms of redox control and novel therapeutic opportunities. Antioxid Redox Signal 18:186-217